Tags : Discloses

Biosimilars

Neuclone Discloses Two Biosimilars Referencing Opdivo (nivolumab) and Keytruda (pembrolizumab)

Shots: The company discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab). The biosimilars are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and Serum Institute of India The disclosure demonstrates NeuClone’s ability to develop multiple biosimilars simultaneously through its NeuMAX platform Additionally, NeuClone and Serum […]Read More

Pharma

Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize

Shots:  Mylan reveals its undisclosed agreement signed on 30 July, 2018 for worldwide commercialization rights for Novartis’ global cystic fibrosis products,TOBI Podhaler and TOBI solution  Company also revealed the reason for keeping the deal undisclosed, as the transaction was under pre-closing confidentiality restrictions The focus of the purchase is to enrich its respiratory units in […]Read More